CLDN10

Across TCGA pan-cancer cohorts, CLDN10 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CLDN10 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CLDN10 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLDN10 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where CLDN10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.811	1.000	.003	21	view →
CCRCC	OS	Median	II,III,IV	0.994	0.688	.010	13	view →
GBM	DFS	Quartile	All	0.877	0.645	.010	4	view →
PDAC	DFS	Tertile	All	0.208	0.407	.031	4	view →
HNSC	OS	Quartile	III,IV	0.696	0.303	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CLDN10–LUAD (DFS)

Open the LUAD breakdown →